(4 intermediate revisions by 2 users not shown) | |||
Line 68: | Line 68: | ||
.style1 {color: #c91f77} | .style1 {color: #c91f77} | ||
#home{ | #home{ | ||
− | background: url(https://static.igem.org/mediawiki/2016/ | + | background: url(https://static.igem.org/mediawiki/2016/5/58/BIT_main-picture1.jpg); |
background-size: cover; | background-size: cover; | ||
background-position: center; | background-position: center; | ||
Line 130: | Line 130: | ||
<li><a href="https://2016.igem.org/Team:BIT/Judging_Form" >Judging</a></li> | <li><a href="https://2016.igem.org/Team:BIT/Judging_Form" >Judging</a></li> | ||
<li><a href="https://2016.igem.org/Team:BIT/Parts_Submission"><span class="style1">Parts</span></a></li> | <li><a href="https://2016.igem.org/Team:BIT/Parts_Submission"><span class="style1">Parts</span></a></li> | ||
− | <li><a href="https://2016.igem.org/Team:BIT/HP/Silver"> | + | <li><a href="https://2016.igem.org/Team:BIT/HP/Silver">Achievement</a></li> |
<li><a href="https://2016.igem.org/Team:BIT/Introduction">Team</a></li> | <li><a href="https://2016.igem.org/Team:BIT/Introduction">Team</a></li> | ||
</ul><!--- End Menu --> | </ul><!--- End Menu --> | ||
Line 176: | Line 176: | ||
</div> | </div> | ||
<div class="indent"> | <div class="indent"> | ||
− | + | <br> | |
<img src="https://static.igem.org/mediawiki/2016/6/65/BIT_basic_part.jpg" class="img-responsive" alt="..."> | <img src="https://static.igem.org/mediawiki/2016/6/65/BIT_basic_part.jpg" class="img-responsive" alt="..."> | ||
− | < | + | <div style="text-indent: 0em;"> |
− | < | + | <center> <font size="1px">miRNA-155 binding site</font></center><br><br> |
− | < | + | </div> |
− | <p> | + | <p>MiRNAs are widely recognized as biomarkers of many diseases. Many studies have shown that, miRNA-155 in patients with breast cancer in the body was significantly higher than normal people. After a thorough literature review , we know the recognition site of miRNA-155, of which the transcription product, mRNA and miRNA-155 base-specific complementary matching, in order to increase its binding specificity with miRNA-155, we design four binding sites for this part, so that when the miRNA-155 presence, it can be quickly identified by this fragment and combine to form double-stranded mRNA complex, blocking the binding of ribosomes, which will inhibit the downstream gene expression, which is called RNA-based gene silencing expression. This can serve as a switch to regulate the expression of downstream genes. |
</p> | </p> | ||
<br><br><br><br><br> | <br><br><br><br><br> | ||
Line 197: | Line 197: | ||
<div class="overlay"> | <div class="overlay"> | ||
<div class="container"> | <div class="container"> | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</div> | </div> | ||
</div> | </div> |
Latest revision as of 03:36, 20 October 2016
<!DOCTYPE html>
Basic Part
MiRNAs are widely recognized as biomarkers of many diseases. Many studies have shown that, miRNA-155 in patients with breast cancer in the body was significantly higher than normal people. After a thorough literature review , we know the recognition site of miRNA-155, of which the transcription product, mRNA and miRNA-155 base-specific complementary matching, in order to increase its binding specificity with miRNA-155, we design four binding sites for this part, so that when the miRNA-155 presence, it can be quickly identified by this fragment and combine to form double-stranded mRNA complex, blocking the binding of ribosomes, which will inhibit the downstream gene expression, which is called RNA-based gene silencing expression. This can serve as a switch to regulate the expression of downstream genes.
Contact Us
Beijing Institute of Technology,
No. 5 South Zhong Guan Cun Street,
Haidian Beijing 100081, P. R. China
Twitter : @igem_BIT
Sina Weibo : @igem_BIT
Website : http://www.bit.edu.cn